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Abstract: The nuclear factor erythroid-derived 2 (NF-E2)-
related factor 2 (Nrf2) is a transcription factor well-
known for its function in controlling the basal and 
inducible expression of a variety of antioxidant and 
detoxifying enzymes. As part of its cytoprotective activ-
ity, increasing evidence supports its role in metabolism 
and  mitochondrial bioenergetics and function. Neuro-
degenerative diseases are excellent candidates for Nrf2-
targeted treatments. Most neurodegenerative conditions 
such as  Alzheimer’s disease, Parkinson’s disease, amyo-
trophic lateral sclerosis, frontotemporal dementia and 
 Friedreich’s ataxia are characterized by oxidative stress, 
misfolded protein aggregates, and chronic inflamma-
tion, the common targets of Nrf2 therapeutic strategies. 
Together with them, mitochondrial dysfunction is impli-
cated in the pathogenesis of most neurodegenerative dis-
orders. The recently recognized ability of Nrf2 to regulate 
intermediary metabolism and mitochondrial function 
makes Nrf2 activation an attractive and comprehensive 
strategy for the treatment of neurodegenerative disorders. 
This review aims to focus on the potential therapeutic 
role of Nrf2 activation in neurodegeneration, with special 
emphasis on mitochondrial bioenergetics and function, 
metabolism and the role of transporters, all of which col-
lectively contribute to the cytoprotective activity of this 
transcription factor.
Keywords: bioenergetics; GSK-3; Keap1; mitochondria; 
neurodegeneration; Nrf2.
Introduction
The nuclear factor erythroid-derived 2 (NF-E2)-related 
factor 2 (Nrf2) is a well-known transcription factor for 
its role in controlling the basal and inducible expres-
sion of a variety of antioxidant and detoxifying enzymes 
(Ishii et al., 2000; McMahon et al., 2001). Together with 
its cytoprotective activity against oxidants and electro-
philes, increasing evidence supports its role in metab-
olism and mitochondrial bioenergetics and function 
(Hayes and Dinkova-Kostova, 2014; Dinkova-Kostova 
and Abramov, 2015).
Nrf2 is encoded by the gene NFE2L2 and belongs to the 
family of basic leucine zipper (bZIP) transcription factors. 
It also contains an upstream cap ‘n’ collar (CNC) domain, 
which contributes to the DNA-binding specificity of this 
family (Moi et  al., 1994; Chevillard and Blank, 2011). In 
vertebrates, other members of the CNC-bZIP family of pro-
teins include p45 NF-E2, the NF-E2-related factor 1 (Nrf1) 
and the NF-E2-related factor 3 (Nrf3) (Andrews et  al., 
1993; Chan et al., 1993; Kobayashi et al., 1999). p45 NF-E2 
is mainly expressed in hematopoietic progenitors and it 
is essential for megakaryocyte maturation and platelet 
 formation (Shivdasani et  al., 1995; Gasiorek and Blank, 
2015). In contrast, Nrf1, Nrf2 and Nrf3 are ubiquitously 
expressed (Sykiotis and Bohmann, 2010). In mammals, 
Nrf1 and Nrf2 are well known for their role in the transcrip-
tional up-regulation of cytoprotective genes in response to 
redox stress (Venugopal and Jaiswal, 1998; Biswas and 
Chan, 2010), whereas Nrf3 has been linked to differen-
tiation, inflammation and carcinogenesis (Chevillard and 
Blank, 2011).
Nrf2 forms a heterodimer with the small muscu-
loaponeurotic fibrosarcoma (sMaf) proteins to bind DNA 
(Itoh et al., 1997). The sMaf proteins are also bZIP factors 
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which form a family of three members, MafF, MafG and 
MafK, with similar functions but different distribution 
(Onodera et  al., 1999). Heterodimerization with sMaf is 
essential to give Nrf2 binding specificity to its target DNA 
sequence (Motohashi et  al., 2004), known as ARE (anti-
oxidant response element) (Venugopal and Jaiswal, 1996; 
Venugopal and Jaiswal, 1998). AREs are upstream regula-
tory sequences that mediate the transcriptional activa-
tion of genes constitutively or in response to an oxidative 
or electrophilic stress signal (Nguyen et  al., 2003). Nrf2 
appears to be more potent in activating ARE-regulated 
genes than Nrf1 (Jaiswal, 2004). Binding of the heterodi-
mer Nrf2/sMaf to the ARE, recruits the general transcrip-
tional machinery for expression of ARE-regulated genes 
(Nguyen et al., 2003; Kensler et al., 2007). Many of these 
genes are implicated in xenobiotics detoxification. Drugs 
and xenobiotics undergo a series of metabolic reactions 
directed to increase the solubility of the molecules in 
water and make them easily removable from the cell. In 
the first step (phase I) drugs are functionalized to make 
them more reactive. The common reactions in this phase 
are oxidation, reduction or hydrolysis and are catalyzed by 
enzymes that can be induced by Nrf2, such as cytochrome 
P450 (Abu-Bakar et  al., 2007; Yokota et  al., 2011); aldo-
keto reductases (AKR) (Ellis, 2007) or NAD(P)H:quinone 
oxidoreductase 1 (NQO1) (Venugopal and Jaiswal, 1996), 
(considered a broad antioxidant and cytoprotector; 
 Dinkova-Kostova and Talalay, 2010). During phase II 
detoxification, xenobiotics are subjected to conjugation 
with different polar compounds, such as glutathione 
(GSH), glucuronic acid or a sulfonic group. Conjugation 
with GSH is catalyzed by glutathione S-transferases (GST) 
and can also be induced by Nrf2 (McMahon et al., 2001; 
Chanas et al., 2002; Aleksunes and Klaassen, 2012). Addi-
tionally, Nrf2 can induce UDP glucuronosyltransferases 
(Enomoto et al., 2001; Kalthoff et al., 2010), which catalyze 
the conjugation of the xenobiotic with glucuronic acid.
Nrf2 is also able to induce different genes related 
to direct endogenous antioxidant systems in the body, 
such as GSH, thioredoxin (TXN) or peroxiredoxin (PRDX) 
systems, for reviews see Tebay et al. (2015) and Hayes and 
Dinkova-Kostova (2014). Those systems generally consist 
of molecules that hold cysteine residues with reactive 
thiol (-SH) groups. The -SH groups are able to reduce oxi-
dized proteins, getting themselves oxidized and forming a 
disulphide bridge (-S-S-). The oxidized forms of the anti-
oxidants are then reduced by reductases, which allow 
regeneration of the pool of the active form of the anti-
oxidant. Generally, the regeneration of the reduced form 
requires the presence of NADPH as a cofactor. Nrf2 is able 
to induce both the catalytic and the modifier subunits of 
glutamate-cysteine ligase together with glutathione reduc-
tase, which are essential for GSH synthesis and regenera-
tion, respectively; thioredoxin and thioredoxin reductase 
1 or peroxiredoxin (MacLeod et al., 2009; Agyeman et al., 
2012; Chorley et al., 2012; Hirotsu et al., 2012). Moreover, 
Nrf2 is able to induce the principal enzymes implicated 
in NADPH generation, namely glucose-6-phosphate 
dehydrogenase (G6PD), malic enzyme 1 (ME-1), isocitrate 
dehydrogenase 1 (IDH-1), and 6-phosphogluconate dehy-
drogenase (PGD) (Thimmulappa et  al., 2002; Lee et  al., 
2003; Wu et al., 2011; Agyeman et al., 2012; Tebay et al., 
2015). NADPH regeneration is crucial in the maintenance 
of redox homeostasis, and is also required for biosynthetic 
reactions (Ying, 2008). In fact, there is growing evidence 
indicating that Nrf2-regulated genes are not restricted to 
redox homeostasis but also implicated in metabolism. It 
has been described that in cancer cells, Nrf2 activation 
through PI3K/Akt, contributes to enhance cell prolifera-
tion by redirecting glucose and glutamine into anabolic 
pathways (Mitsuishi et  al., 2012b). In addition to carbo-
hydrate metabolism regulation, Nrf2 is also implicated in 
lipid metabolism, as it promotes β-oxidation of fatty acids 
(Wu et  al., 2011; Ludtmann et  al., 2014), and negatively 
regulates genes associated with lipid biosynthesis (Yates 
et  al., 2009) (reviewed in Hayes and Dinkova-Kostova, 
2014). The involvement of Nrf2 in mitochondrial bioener-
getics is getting increasing attention and will be discussed 
later.
Nrf2 structure and regulation
Nrf2 activity is tightly controlled. Under basal conditions, 
Nrf2 is maintained at low levels, as it is continuously being 
degraded in the proteasome. There are different ubiquitin 
ligase systems responsible for targeting Nrf2 for degrada-
tion in the proteasome. The best known is the Cullin  3 
(Cul3) RING-box 1 (RBX1) E3 ubiquitin ligase complex, 
which needs the substrate adaptor protein Kelch-like ECH-
associated protein 1 (Keap1) to ubiquitinate Nrf2 (Cullinan 
et  al., 2004; Kobayashi et  al., 2004; Zhang et  al., 2004). 
Keap1 is a cysteine-rich regulatory protein located in the 
cytoplasm (Itoh et al., 1999; Holland and Fishbein, 2010). 
Keap1 dimerizes and binds Cul3 through its BTB domain 
(Furukawa and Xiong, 2005), while its Kelch domain is 
able to interact with the Neh2 domain of Nrf2 (Itoh et al., 
1999; McMahon et  al., 2006). By a cyclical mechanism, 
Nrf2 is then ubiquitinated and transferred to the protea-
some, where it is degraded, while Keap1 is regenerated 
(Baird et  al., 2013; Baird et  al., 2014) (Figure  1A). In the 
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Figure 1: Regulation of Nrf2 activity by Keap1 and GSK-3.
Two main ubiquitin ligase systems are responsible for targeting Nrf2 for degradation in the proteasome. (A) Cullin 3 (Cul3) RING-box 1 
(RBX1) E3 ubiquitin ligase complex, binds the adaptor protein Keap1 dimer through its BTB domain. Keap1 is then able to interact with the 
Neh2 domain of Nrf2, allowing the ubiquitination of Nrf2 and its degradation in the proteasome. (B) Electrophiles and oxidants (termed 
inducers) chemically modify specific Cys sensor residues of Keap1, leading to conformational changes that prevent Nrf2 ubiquitination. Nrf2 
then accumulates and translocates to the nucleus, where it forms a dimer with the small musculoaponeurotic fibrosarcoma (sMaf) proteins 
to bind ARE regions in the DNA and mediate the up-regulation of its target genes. (C) The adaptor protein β-TrCP binds the SCF ubiquitin 
ligase complex (formed by the Skp1 adaptor, Cullin 1 and Rbx1, where the E2-ubiquitin conjugate binds). Glycogen synthase kinase-3 
(GSK-3) phosphorylates Nrf2 in the Neh6 domain. Phosphorylated Nrf2 is then recognized by β-TrCP, targeting the protein for degradation 
through this system. (D) Certain signaling pathways, such as PI3K/Akt, are able to phosphorylate GSK-3 and inactivate it, therefore allow-
ing Nrf2 accumulation.
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absence of Keap1, Nrf2 is no longer sequestered in the 
cytoplasm and degraded, and is able to translocate to the 
nucleus and allow the transcription of its target genes.
Keap1 contains reactive cysteine residues, some of 
which act as sensors of electrophilic and/or oxidative 
signals (Dinkova-Kostova et al., 2002; Eggler et al., 2005; 
Fourquet et al., 2010; McMahon et al., 2010; Saito et al., 
2015). Under stress conditions, certain Keap1 cysteine 
residues are chemically modified, which prevents Nrf2 
ubiquitination and degradation, allowing its stabiliza-
tion and the transcription of its target genes (Holland and 
Fishbein, 2010) (Figure 1B). It has also been described 
that some electrophilic lipids, such as the cyclopentenone 
prostaglandin, 15-deoxy-Δ12,14 –prostaglandin J2 (which 
serves as a model to study the effects of lipid peroxida-
tion products derived by the reaction of reactive oxygen/
nitrogen species with unsaturated fatty acids), are able to 
induce Nrf2 by modifying thiol groups of Keap1 (Levonen 
et al., 2004). Another mechanism by which modification 
of certain cysteines in Keap1 leads to diminished degrada-
tion of Nrf2 is by decreasing the affinity of Keap1 for Cul3, 
and subsequently diminishing Nrf2 ubiquitination (Gao 
et al., 2007; Eggler et al., 2009).
The p62-dependent autophagic degradation of Keap1 
is another mechanism of Nrf2 activation and cytoprotec-
tion (Taguchi et  al., 2012). This mechanism has been 
shown to occur in response to lipotoxicity (Park et al., 
2015) or to be mediated by sestrins (Bae et al., 2013). p62 
has also been reported to interact with the Nrf2-binding 
site on Keap1, competing with Nrf2, and thus preventing 
its degradation (Jain et al., 2010; Komatsu et al., 2010; 
Lau et  al., 2010). This is especially prominent under 
conditions when p62 is phosphorylated (Ichimura et al., 
2013).
Although Keap1 is the most studied regulator of Nrf2 
activity, more recently the role of another E3-ubiquitin 
ligase adaptor, β-TrCP, was described, together with the 
SCF ubiquitin ligase complex. This mechanism, which is 
independent of Keap1, is regulated by glycogen synthase 
kinase-3 (GSK-3), which phosphorylates Nrf2 in the Neh6 
domain, targeting the protein for degradation by the 
proteasome through SCF/β-TrCP and therefore inhibit-
ing Nrf2 activity (Rada et al., 2011; Chowdhry et al., 2013) 
(Figure  1C). It has been proposed that while Keap1 acts 
as a major sensor of electrophiles and oxidants, GSK-
3/β-TrCP system participates in receptor-mediated signal 
transduction, modulating the Nrf2 levels in response to 
transient metabolic demands (Cuadrado, 2015). This 
mechanism could involve pathways that can participate 
in GSK-3 regulation such as PI3K/Akt or WNT signaling 
(Figure 1D).
Nrf2 activators
A wide range of compounds are able to react with 
cysteine sensors of Keap1, inducing conformational 
changes that prevent Nrf2 ubiquitination, leading to 
its accumulation. The majority of the small molecule 
pharmacological activators of Nrf2 are electrophilic and 
structurally varied, and include cyano enones, such as 
TBE-31, a tricyclic compound with two highly reactive 
Michael acceptor groups (Liby et al., 2008). TBE-31 binds 
to its target in a reversible covalent mode, and represents 
one of the most potent Nrf2 activators known to date. 
Sulforaphane (SFN), an isothiocyanate obtained from 
cruciferous vegetables such as broccoli, is one of the 
most potent naturally occurring Nrf2 activators (Zhang 
et al., 1992). The fumaric acid ester dimethyl fumarate is 
also able to stabilize Nrf2 (Spencer et  al., 1990), and it 
has been successfully used for the treatment of psoriasis 
(Kolbach and Nieboer, 1992). Its oral formulation BG-12 
has been recently approved for the treatment of multi-
ple sclerosis (Linker et  al., 2011). Other molecules able 
to stabilize Nrf2 are the quinone compound tert-butylhy-
droquinone (tBHQ) (Li et al., 2005) and the triterpenoids 
bardoxolone methyl (Dinkova-Kostova et al., 2005) and 
RTA 408 (Probst et al., 2015), both of which are currently 
in clinical trials.
All the Nrf2 activators presented above exemplify elec-
trophilic activators of Nrf2, but there is also an increasing 
interest in developing non-electrophilic molecules that 
can activate this pathway (see Richardson et al., 2015, for 
a review).
Activating Nrf2 can represent an excellent pharma-
cological strategy for diseases in which oxidative stress 
or mitochondrial dysfunction are key features of the 
pathology. However, it is also important to examine the 
potential toxicity that these molecules may exhibit (de 
Zeeuw et  al., 2013), specially regarding to the dosing 
regimen. It should also be considered that in certain 
context, Nrf2 activation could be detrimental. One of the 
major concerns is related to the association between Nrf2 
activation and cancer progression. It has been suggested 
that the increase in cytoprotective activity in the cell 
and the decrease in ROS levels may promote the survival 
of tumor cells in certain situations. Gain-of-function 
NFE2L2 mutations or loss-of-function KEAP1 mutations 
have been found in different carcinomas, and decreased 
expression of Keap1 or increased expression of Nrf2 
have been associated with poor prognosis (Solis et  al., 
2010). For those reasons, taking into account the context 
is essential in designing Nrf2 therapeutic approaches 
(Sporn and Liby, 2012).
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Nrf2 in metabolism and 
 mitochondrial function
Although most of the studies up to date have been focused 
on the antioxidant properties of Nrf2 activation, there is 
increasing evidence pointing at the role of Nrf2 in metab-
olism and mitochondrial function. There are several 
mechanisms by which Nrf2 may affect metabolism. One of 
them is by directly activating the transcription of enzymes 
containing ARE-sequences in their gene promoters. The 
presence of ARE-sequences has been described in the 
promoters of the genes encoding the Peroxisome Prolif-
erator-Activated Receptor γ (PPARγ) and the Retinoid X 
Receptor α (RXRα) (Pi et  al., 2010; Chorley et  al., 2012). 
RXRα forms part of the retinoic acid receptors (RARs), 
which are nuclear receptors that mediate the biological 
effects of retinoids. These receptors function as transcrip-
tion factors by binding as homodimers or heterodimers 
with other nuclear receptors such as PPARγ to specific 
sequences in the promoters of target genes. PPARγ is a 
nuclear receptor that regulates adipocyte differentiation 
and adipogenesis. For this reason, it was suggested that 
Nrf2 regulation of both RXRα and PPARγ has implications 
for response to retinoid treatments and adipogenesis 
(Chorley et al., 2012).
Recent studies have used chromatin immunopre-
cipitation-sequencing (ChIP-Seq) to identify human 
Nrf2- regulated genes in lymphoid cells treated with sul-
foraphane (Chorley et  al., 2012) or in mouse embryonic 
fibroblasts (MEF) with constitutive accumulation of Nrf2 
(Keap1-/-) or Nrf2 depletion (Nrf2-/-) (Malhotra et al., 2010). 
Together with known Nrf2 targets, such as HMOX1, which 
participates in the heme degradation pathway, or fer-
ritin (FTL and FTH1), implicated in iron homeostasis, or 
those implicated in antioxidant signaling and detoxifi-
cation (e.g. TXNRD1, GSTM), these authors have identi-
fied several novel Nrf2 targets. An example of an enzyme 
linked to metabolism and positively regulated by Nrf2 is 
transaldolase 1, whose gene TALDO1 contains an ARE 
sequence (Chorley et  al., 2012). Transaldolase 1 is a key 
enzyme in the nonoxidative pentose phosphate pathway, 
providing ribose-5-phosphatase and NADPH for nucleic 
acid and lipid biosynthesis. Among others, they found 
that several genes involved in mitochondrial function are 
upregulated by Nrf2, such as ABCB6, which encodes a 
member of a family of ATP-binding cassette transporters 
(Chorley et al., 2012).
Also, it is important to note that together with the 
direct binding of Nrf2 to the ARE sequences in the DNA, 
Nrf2 can indirectly regulate many other proteins. For 
example, Nrf2 directly controls the expression of MafG, 
one of the transcriptional coactivators with which it forms 
a heterodimer to bind DNA. It was found that Nrf2-MafG 
heterodimer directly regulates numerous genes involved in 
glucose metabolism through AREs. Among the pathways 
found in this study, there was a notable contribution of 
genes regulating pyruvate metabolism, glycolysis and glu-
coneogenesis (Hirotsu et al., 2012). But, independently of 
the Nrf2-MafG mediated transcription, MafG can also form 
homodimers and/or heterodimers with other members of 
the CNC family, thus activating different genes than Nrf2-
MafG (Kimura et al., 2007).
Another important mechanism by which Nrf2 can 
alter metabolism or mitochondrial function is by prevent-
ing the oxidative thiol modifications that can modulate 
the function of proteins implicated in metabolic path-
ways. It has been described that mitochondrial ROS can 
reversibly modify thiol groups present in several enzymes 
implicated in carbohydrate and lipid metabolism, affect-
ing their activity (Hurd et al., 2007). Most of the enzymes 
found in the cited study are involved in fatty acid oxidation 
(FAO) (carnitine acetyltransferase, very long chain acyl-
CoA dehydrogenase, propionyl-CoA carboxylase); and 
also in the regulation of pyruvate dehydrogenase (PDH) 
by pyruvate dehydrogenase kinase 2, which inhibits PDH 
and prevents the entry of pyruvate from glycolysis into 
the Krebs cycle (Hurd et al., 2007). It has also been well 
documented that glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), an enzyme that catalyzes the sixth step 
of glycolysis, possesses a cysteine in its active site, which 
can be oxidized by reactive oxygen and nitrogen species 
(Ishii et  al., 1999). This oxidative modification is able to 
inhibit its dehydrogenase activity, not only affecting the 
glycolytic metabolism, but also promoting apoptosis, 
which has important implications in neurodegenerative 
disorders such as Alzheimer’s disease (AD) (Butterfield 
et  al., 2010). As it has been reviewed in (Brandes et  al., 
2009), there are other metabolic enzymes that can be 
modified by thiol:disulphide exchange, such as creatine 
kinase, glycogen synthase or protein phosphatase-I. In 
this context, one of the mechanisms by which Nrf2 may 
affect lipid and carbohydrate metabolism is by preventing 
the redox modifications of these sensitive thiol groups by 
mitochondrial ROS.
Nrf2 in brain and  neurodegenerative 
diseases
Neurodegenerative diseases are excellent candidates 
for Nrf2-targeted treatments. Most neurodegenerative 
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disorders such as AD, Parkinson’s disease (PD), amyo-
trophic lateral sclerosis (ALS), frontotemporal demen-
tia, Friedreich’s ataxia or Hungtington disease are 
characterized by oxidative stress and misfolded protein 
aggregates, so targeting both alterations has always 
been considered an important therapeutic approach for 
these diseases (Burchell et al., 2010). The ability of the 
Nrf2 pathway to regulate genes associated with antioxi-
dant defense, autophagy and proteasome activation has 
been attracting attention to the use of Nrf2 activators as 
therapeutic strategies for neurodegenerative diseases 
(reviewed in (Hensley and Harris-White, 2015; Johnson 
and Johnson, 2015).
The importance and potential of Nrf2 activation for the 
treatment of neurodegenerative disorders has been dem-
onstrated with the approval of BG-12, the oral formulation 
of the Nrf2 inducer dimethyl fumarate, for the treatment 
of multiple sclerosis (Linker et  al., 2011; Kawalec et  al., 
2014). Currently, REATA Pharmaceuticals has initiated a 
clinical trial with a novel Nrf2 activator, named RTA 408, 
for the treatment of Friedreich’s ataxia (ClinicalTrials.gov, 
NCT02255435). This neurodegenerative disease is caused 
by deficiency of the protein frataxin, which causes the dis-
ruption of iron-sulfur cluster biosynthesis, mitochondrial 
iron overload and an increased sensitivity to oxidative 
stress, mainly due to a decrease in the expression of Nrf2 
(Shan et al., 2013).
Although most studied, oxidative stress and protein 
aggregation are not the only Nrf2-related targets for the 
treatment of neurodegenerative diseases. Beyond them, 
metabolism and mitochondrial dysfunction are common 
alterations found in these disorders, and can benefit from 
Nrf2 activation.
Mitochondria are involved in essential cellular pro-
cesses. They are the main source of energy in the cell, by 
providing ATP through oxidative phosphorylation and 
harboring several metabolic pathways such as FAO and 
the TCA cycle. In addition, they are fundamental regula-
tors of calcium homeostasis and signaling. Mitochondria 
also represent a major source of reactive oxygen species in 
the cell (mainly as a result of the electron transport chain 
activity) and play a key role in apoptosis.
As a result of their constant activity and signaling, 
cells in the central nervous system have a high require-
ment for energy, and are especially vulnerable to mito-
chondrial dysfunction. Decreased ATP production is a 
common hallmark of neurodegenerative diseases and 
can be caused by various mechanisms, such as impaired 
activity of any of the complexes of the respiratory chain, 
alterations in glucose uptake, glycolysis, TCA cycle or 
uncoupling (Burchell et al., 2010).
Nrf2, mitochondrial bioenergetics 
and neurodegenerative disorders
Work from our laboratory has shown the role of Nrf2 in 
mitochondrial bioenergetics using primary neuronal cul-
tures, MEFs and isolated mitochondria from wild-type 
and mice where Nrf2 has been genetically induced by 
knockdown of Keap1 (Keap1 KD) or disrupted (Nrf2 KO) 
 (Holmstrom et  al., 2013). In cells where Nrf2 was inacti-
vated, mitochondrial function was impaired as demon-
strated by the decrease in the mitochondrial membrane 
potential (MMP), an indicator of the mitochondrial health. 
In Nrf2 KO cells, MMP is maintained by F1F0 – ATPase 
working in reverse rather than by respiration. This was not 
caused by a decrease in the activity of the respiratory com-
plexes, but instead by a lower availability of substrates for 
complexes I and II, as it was demonstrated by the strongly 
decreased NADH and FADH2 pools in Nrf2 KO, compared to 
WT (Holmstrom et al., 2013). In parallel, ATP production 
was reduced due to a less efficient oxidative phosphoryla-
tion, and was maintained mainly through activation of 
glycolysis (Holmstrom et al., 2013). Conversely, constitu-
tive Nrf2 activation was able to increase the availability 
of substrates for respiration, enhancing ATP production 
and increasing the mitochondrial membrane potential 
 (Holmstrom et al., 2013).
Reduced ATP production and O2 consumption were 
also found in a different model of Nrf2 deficiency (Kim 
et al., 2011). In cells with a high-energy demand such as 
neurons, the dysfunction in oxidative phosphorylation 
and the decrease in ATP levels may be detrimental, espe-
cially because of their low glycolytic capacity. Also, the 
diversion of glucose from the pentose phosphate pathway 
to glycolysis in neurons can affect the regeneration of 
glutathione and result in oxidative stress and apoptosis 
(Herrero-Mendez et al., 2009).
These results suggest that activation of Nrf2 can 
lead to an improvement in the bioenergetics features of 
cells with impaired substrates availability, and this may 
be very important in cells with high-energy demand as 
neurons. Inhibition of mitochondrial respiration due to 
reduced substrates from the TCA cycle has been previ-
ously shown in the PINK1 model of PD, leading to dopa-
mine-induced cell death (Gandhi et  al., 2009; Abramov 
et  al., 2011). This can be prevented either by providing 
the cells directly with mitochondrial substrates, and also 
by treating them with the Nrf2 activators sulforaphane 
or RTA 408, which are able to revert the bioenergetic 
alterations caused by the lack of substrates for the TCA 
cycle and prevent the dopamine-induced cell death in 
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this model  (Dinkova-Kostova et al., 2015). Mitochondrial 
complex I dysfunction is a well-known pathophysiologi-
cal characteristic of PD. 1-Methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP), an inhibitor of complex I, is able to 
induce the clinical and pathological hallmarks of PD, and 
for this reason, is used as a model of the disease. Nrf2 
activators have been found to be neuroprotective in the 
MPTP model of PD (Burton et al., 2006; Chen et al., 2009; 
Jazwa et al., 2011). The authors found that the deficiency 
in Nrf2 increased the sensitivity to the complex I inhibi-
tor, while its activation in astrocytes was able to protect 
against MPTP-mediated toxicity. The protective role of 
Nrf2 in PD is also supported by a multicentre study which 
discovered that variations in the gene encoding Nrf2 are 
associated with risk and age at onset of idiopathic PD, 
finding a protective haplotype of the gene with decreased 
risk and delayed onset (von Otter et al., 2010).
It is not yet well known by which mechanism Nrf2 
activation is able to increase the availability of substrates 
for the TCA cycle, but Nrf2 is able to regulate several 
enzymes implicated in glucose metabolism (Hirotsu et al., 
2012; Singh et al., 2013). The latter study shows a role for 
Nrf2 in the regulation of the carbon flux through the TCA 
cycle (Singh et  al., 2013). Pyruvate, the final product of 
glycolysis, is able to enter the TCA cycle as acetyl-CoA, 
in a reaction catalyzed by the pyruvate dehydrogenase 
complex, but also as oxaloacetate (OAA), in a reaction 
catalyzed by pyruvate carboxylase. These authors show 
that in the absence of Nrf2, there is a dramatic reduction 
in both substrates entry into the TCA cycle, together with 
a decrease in glucose oxidation (Singh et al., 2013). Con-
versely, increased Nrf2 activity led to enhanced glucose 
flux trough the TCA cycle.
As discussed previously in this review, a possible 
mechanism would be the potential role of Nrf2 in prevent-
ing the oxidation of thiol groups present in key enzymes 
in these pathways, such as GAPDH or pyruvate dehydro-
genase kinase 2. It has been also proposed that in cancer 
cells, Nrf2 plays a role in increasing glucose uptake and 
glycolytic activity, finally leading to an increase in the 
supply of glycolytic intermediates ( Mitsuishi et al., 2012a).
Nrf2 is also able to up-regulate ME1 (Thimmulappa 
et al., 2002; Lee et al., 2003; Chorley et al., 2012), which 
encodes the cytosolic NADP+-dependent malic enzyme 1 
(ME1) that generates NADPH. The activity of this enzyme, 
the reversible oxidative decarboxylation of malate to pyru-
vate, links the glycolytic and citric acid cycles. Malate rep-
resents one of the main Krebs cycle intermediates exported 
from the mitochondria to the cytosol, where cytosolic ME1 
can regenerate pyruvate that can cycle back to the mito-
chondria. In this reaction NADP+ is converted to NADPH, 
making ME1 one of the main cytosolic sources of NADPH 
production, which can be then utilized for both fatty acid 
synthesis and antioxidant protection. Malic enzyme 1 is 
considered an anaplerotic enzyme for the TCA cycle. For 
the normal function of the Krebs cycle, the levels of TCA 
intermediates must remain constant. As many reactions 
need some of these intermediates as substrates, they 
have to be extracted from the TCA in the mitochondria 
through cataplerotic reactions. In the opposite direction, 
anaplerotic reactions replenish the TCA cycle intermedi-
ates to maintain the function of the mitochondrial cycle. 
Cytosolic ME1 activity has an essential role in replenish-
ing the TCA cycle in astrocytes, sustaining the pyruvate 
recycling activity (McKenna et al., 1995; Calvetti and Som-
ersalo, 2012), and Nrf2-dependent activation of ME1 may 
be important to maintain the TCA cycle in astrocytes ena-
bling neurotransmitter synthesis and recycling.
It is also noteworthy that the impaired substrate avail-
ability caused by the lack of Nrf2 in glioneuronal cultures 
from Nrf2 KO mice was responsible for the increased mito-
chondrial ROS production found in this model (Kovac 
et  al., 2015). In basal conditions, these cells presented 
an increased rate of mitochondrial ROS production com-
pared to WT cells. While inhibition of complex I by rote-
none did nöt increase further the rate of ROS, suggesting 
that complex I activity was already impaired at basal 
levels; application of pyruvate, a substrate for the TCA 
cycle, diminished the rate of ROS production (Kovac et al., 
2015). This finding supports the link between metabolic 
pathways and redox homeostasis within the cell.
Nrf2 and lipid metabolism
As reviewed in (Hayes and Dinkova-Kostova, 2014), Nrf2 
positively regulates lipases involved in phospholipids and 
triglycerides degradation and enzymes involved in FAO. 
Conversely, it is also able to negatively regulate genes 
implicated in lipid biosynthesis, fatty acid desaturation 
and fatty acid transport. Work from our laboratory shows 
an additional role for Nrf2 in mitochondrial bioenerget-
ics by controlling the efficiency of FAO. In the absence of 
glucose, Nrf2 deficiency induced a much stronger loss of 
MMP suggesting that FAO, which would provide substrates 
for the TCA cycle during glucose deprivation, is altered in 
the absence of Nrf2 (Ludtmann et  al., 2014). Addition of 
fatty acids stimulated respiration and increased the ATP 
production both in WT and Keap1 KO MEFs, with ATP 
levels increasing faster in the latter. In contrast, in the 
absence of Nrf2, application of palmitoylcarnitine did 
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not affect the ATP levels, indicating that in the absence of 
Nrf2, the efficiency of FAO is significantly reduced, altering 
mitochondrial metabolism (Ludtmann et al., 2014). These 
results are in agreement with another report that shows 
that resveratrol, an inducer of Nrf2, is able to increase 
fatty acid utilization in FAO disorders (Bastin et al., 2011).
Although the existing knowledge points at glucose as 
the main source of energy in the brain (either as glucose 
or lactate), it has been also shown that fatty acids can be 
used by the brain and contribute to the energy production 
in astrocytes (Ebert et al., 2003). Moreover, some reports 
found alterations in FAO in neurodegenerative disorders 
and also neuroprotective effects associated to the activa-
tion of FAO, which suggest that Nrf2-induced FAO can be 
a potential therapeutic target. For example, it was shown 
that the levels of two of the main enzymes for β-oxidation, 
acyl-coenzyme A dehydrogenase and mitochondrial tri-
functional enzyme subunit α are reduced in AD patients 
(Choi et  al., 2014). In a different study, 3-hydroxyacyl-
CoA dehydrogenase, which catalyzes the oxidation of 
3-hydroxyacyl-CoAs in the mitochondrial FAO, was shown 
to protect against the MPTP-induced impairment of oxida-
tive phosphorylation and ATP production in this model of 
PD (Tieu et al., 2004).
There has also been described a relationship between 
Nrf2 activation, phospholipid metabolism and endocan-
nabinoids. Nrf2 up-regulates ABHD4, which has been 
described as a main regulator of N-acyl phospholipid 
metabolism in the mammalian nervous system (Lee et al., 
2015). N-acyl phospholipids are considered aytipical lipids 
implicated in the biosynthesis of lipid mediators such as 
endocannabinoids. In parallel, it has been shown that 
phenolic endocannabinoids like N-acyl 5-HT, present in 
the brain exert a cytoprotective action against glutamate-
induced oxidative damage of HT-22 cells possibly by an 
Nrf2-mediated mechanism (Jin et al., 2014).
As discussed before, Nrf2 is able to induce both PPARγ 
and RXRα. These receptors are not only implicated in 
adipocyte differentiation, but also regulate ApoE (Yue 
and Mazzone, 2009). ApoE is the main apolipoprotein 
in the brain, which facilitates the trafficking of lipids in 
the central nervous system, and has been also shown to 
modulate Aβ deposition and clearance in an isoform-
dependent manner (Castellano et  al., 2011). Possession 
of an APOE ε4 allele is the strongest risk factor for spo-
radic AD, and has been linked to decreased efficiency of 
Aβ clearance (Castellano et al., 2011). The production of 
ApoE is regulated by liver X receptors (LXR) that function 
as cholesterol sensors and form heterodimers with retin-
oid receptors RXRs, promoting the transcription of APOE 
and other genes involved in cholesterol metabolism such 
as the ones that encode the ABC transporters ABCA1 and 
ABCG1 (Hong and Tontonoz, 2014). It has been shown 
that ligands of PPARγ are able to induce the expression 
of LXR, and there is strong evidence that activation of 
either PPARγ, LXR or RXR ameliorate Aβ pathology and 
behaviour in different animal models of AD (Yamanaka 
et al., 2012; Skerrett et al., 2015). In fact, the PPARγ agonist 
pioglitazone is currently undergoing clinical trials for the 
treatment of AD (Geldmacher et al., 2011). In this context, 
Nrf2 activation would potentially have beneficial effects, 
as it is able to induce not only PPARγ but also RXRα and, 
moreover, ABC transporters, as will be discussed in the 
next section. A summary of the role of Nrf2 activation in 
mitochondrial function and metabolism in neurodegen-
erative diseases can be found in Figure 2.
Nrf2 and drug transporters
Nrf2 activation is related with the up-regulation of two 
different transporter families in the cell: ATP-binding 
 cassette (ABC) transporters and solute carrier (SLC) trans-
porters (Table 1).
ABC transporters
ABC transporters are divided into different subfamilies 
(from ABCA to ABCG) and are expressed in every cell type 
of the brain mediating the transport of a variety of sub-
stances. Its role in the brain and in neurodegenerative 
diseases is mainly attributed to their function or dysfunc-
tion at the blood brain barrier (BBB) (Pahnke et al., 2014), 
where they are determining elements for the delivery of 
drugs to the central nervous system. ABC transporters 
function to pump substrates outside the cell by hydrolyz-
ing ATP, and together with a wide spectrum of drugs and 
xenobiotics, they can transport many different metabolites 
and signaling molecules, and thus have a very important 
function for neuroprotection and cellular communication.
Nrf2 plays a role in the up-regulation of the major 
ABC transporters in the brain (Table 1), most of which 
have been implicated in neurodegenerative diseases. 
ABCC1 encodes the protein MRP1, member of the multi-
drug resistance protein family. It works as a multispecific 
organic anion transporter whose substrates are oxidized 
glutathione, glucoronides and sulfate conjugates of 
steroid hormones and bile salts, among others. It was 
shown both in a mouse model of AD and in a cellular 
model, that ABCC1/MRP1 expression is induced in the 
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Figure 2: Nrf2 activation: its role in mitochondrial function and metabolism in neurodegenerative diseases.
Nrf2 activation is a potential therapeutic strategy for neurodegenerative diseases, not only for its role in antioxidant defense, autophagy 
and proteasome activation; metabolism and mitochondrial dysfunction are common alterations in these disorders, that can also benefit 
from Nrf2 activation. Nrf2 activation is able to increase the mitochondrial membrane potential (MMP), the availability of substrates for 
respiration and the ATP production in the mitochondria, improving the bioenergetics features of cells, which is especially important in cells 
with high-energy demands such as neurons; its deregulation is a hallmark of several neurodegenerative disorders. Nrf2 activation has been 
demonstrated to be beneficial in the PINK1 and MPTP models of Parkinson’s disease, which present substrates availability impairment 
and complex I dysfunction. Although the mechanism has not been fully elucidated, Nrf2 is able to regulate enzymes implicated in glucose 
metabolism, flux of glucose through the TCA cycle, and has a potential role in regulating the pyruvate dehydrogenase complex (PDH) (which 
controls the entrance of pyruvate into the mitochondria) and glucose uptake.Nrf2 regulates malic-enzyme 1 (ME-1), an anaplerotic enzyme 
that generates NADPH and regenerates pyruvate that can cycle back to the mitochondria. Its activation is important in astrocytes, enabling 
neurotransmitter synthesis and recycling. Nrf2 controls the efficiency of mitochondrial fatty acid oxidation, which can be used in the brain 
and contribute to energy production in astrocytes. Alterations in fatty acid oxidation have been shown in Alzheimer’s and Parkinson’s dis-
eases. Nrf2 enhances the activity of enzymes of the pentose phosphate pathway that generate NAPDH, which can be used for glutathione 
(GSH) and other antioxidants regeneration.
Unauthenticated
Download Date | 6/1/16 11:31 AM
392      N. Esteras et al.: Nrf2, mitochondria and neurodegeneration
Table 1: Family members of the ABC and SLC transporters regulated by Nrf2.
Gene   Protein   Function   Refs
ABCC1
(MRP subfamily of 
ABC transporters)
  MRP1
Multidrug resistance protein 1
  –  Multispecific organic anion transporter 
(oxidized glutathione, glucuronides, sulfate 
conjugates of steroid hormones and bile salts)
  Hayashi et al., 2003; 
Udasin et al., 2015
ABCC2
(MRP subfamily of 
ABC transporters)
  MRP2
Multidrug resistance protein 2
  – Multidrug resistance   Maher et al., 2007; Wang 
et al., 2014
ABCC3
(MRP subfamily of 
ABC transporters)
  MRP3
Multidrug resistance protein 3
  – Multidrug resistance
– Excretion of organic anions
  Maher et al., 2007; 
Shelton and Jaiswal, 
2013
ABCC4
(MRP subfamily of 
ABC transporters)
  MRP4
Multidrug resistance protein 3
  – Multidrug resistance
– Pump organic anions
– Prostaglandin-mediated cAMP signaling
  Maher et al., 2007; Cheng 
et al., 2011; Hirotsu 
et al., 2012; Shelton and 
Jaiswal, 2013
ABCA8B
(ABC-1 
subfamily of ABC 
transporters)
  ABCA8B   – Transport of lipophilic compounds
– Digoxin metabolism
– Lipid metabolism
  Hirotsu et al., 2012
ABCG2 
(White 
subfamily of ABC 
transporters)
  BRCP
Breast cancer resistance protein
  – Multidrug resistance
–  Xenobiotic transporter (mitoxantrone, 
anthracycline)
  Shelton and Jaiswal, 
2013; Wang et al., 2014
ABCB1
(MDR/TAP 
subfamily of ABC 
transporters) 
  MDR1
P-glycoprotein
  – Transporter in the BBB
– Multidrug resistance
– Efflux pump for xenobiotic compounds
  Wang et al., 2014
SLC7A11   xCT, CCBR1
solute carrier family 7 (anionic 
amino acid transporter light chain, 
xc- system), member 11
  – Light chain of the Xc(-) transporter system
–  Transport system specific for cysteine (in its 
anionic form) in exchange for glutamate
  Chorley et al., 2012; 
Hirotsu et al., 2012
SLC1A4   ASCT1
solute carrier family 1 (glutamate/
neutral amino acid transporter), 
member 4
  –  High-affinity glutamate and neutral amino 
acid transporter
  Hirotsu et al., 2012
SLC6A9   GlyT1
solute carrier family 6 
(neurotransmitter transporter, 
glycine), member 9
  – Glycine transporter   Hirotsu et al., 2012
SLC48A1   HRG1
solute carrier family 48 (heme 
transporter), member 1
  – Heme transporter   Chorley et al., 2012; 
Hirotsu et al., 2012
SLC22A23   solute carrier family 22, member 23   – Organic cation/anion/zwitterion transporter   Hirotsu et al., 2012
SLC19A2   THTR1
solute carrier family 19 (thiamine 
transporter), member 2
  – Thiamin transporter protein   Hirotsu et al., 2012
SLC14A1   UT1
solute carrier family 14 (urea 
transporter), member 1 (Kidd blood 
group)
  – Urea transport in erythrocytes
Basis for the Kidd blood group system
  Hirotsu et al., 2012
SLC16A6   MCT6
solute carrier family 16, member 6
  – Monocarboxylate transporter family   Chorley et al., 2012
SLC3A2   MDU1
solute carrier family 3 (amino acid 
transporter heavy chain), member 2
  –  Heavy chain of an heterodimer covalently 
bound through di-sulfide bonds to one or 
several light chains
– Calcium levels
– L-type amino acids transport
  Chorley et al., 2012
SLC12A8   CCC9
Solute carrier family 12, member 8
  –  Electroneutral cation/Cl- co-transporter family
– Psoriasis susceptibility
  Chorley et al., 2012
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early stages of AD pathogenesis by less aggregated Aβ, 
promoting the GSH release from astrocytes, which pro-
tects the cells temporarily from oxidative stress (Ye et al., 
2015). In contrast, later in the disease, or with prolonged 
incubation with aggregated Aβ, the levels of MRP1 are 
reduced (Ye et  al., 2015). The repercussion of this trans-
porter in AD is much stronger. MRP1, together with MDR1, 
or P-glycoprotein (encoded by the ABCB1 gene) have been 
critically implicated in the clearance of endogenous pro-
teins, as amyloid-β (Aβ), from the brain, being discovered 
as major Aβ exporting molecules at the BBB (reviewed in 
Pahnke et  al., 2014). The alteration of the expression or 
function of these transporters in the brain may contrib-
ute to the aggregation of Aβ, and its accumulation in the 
blood vessels, which is known as cerebral amyloid angio-
pathy (CAA). CAA is associated with cognitive decline, and 
represents a hallmark of AD and an important cause of 
vascular dementia. It was found in different mice models 
and human tissue, that ABCB1 expression is decreased in 
patients with capillary CAA (capCAA), a disease charac-
terized by Aβ-deposits in the cerebral capillaries (Carrano 
et  al., 2014). The decline of the levels of the transporter 
at the BBB occurs during normal aging, and is positively 
correlated with the accumulation of Aβ (Silverberg et al., 
2010). Due the contribution of ABC transporters on Aβ 
clearance in AD, they have been proposed as potential 
therapeutic targets (Krohn et al., 2011). Moreover, ABCB1 
dysfunction has been also associated with other neuro-
degenerative disorders such as PD, progressive supranu-
clear palsy (PSP) or genetically associated with depressive 
disorders (Bernstein et al., 2014). As most of these efflux 
pumps are up-regulated by Nrf2, using Nrf2 activators may 
provide an important tool to increase the activity of ABC 
transporters.
MRP4, the multidrug resistance-associated protein 4, 
encoded by gene ABCC4, is also up-regulated by Nrf2 
(Chan et al., 1993; Maher et al., 2007; Yates et al., 2009; 
Kalra et al., 2011; Kalra et al., 2012) and is able to trans-
port not only drugs, but many different signaling mol-
ecules such as cAMP, cGMP, ADP or prostaglandins (PG), 
playing a very important role in cellular communication 
and signaling (reviewed in Wen et  al., 2015). The clear-
ance of PGs (which are anionic) from the brain to either 
the blood or the cerebrospinal fluid is mediated by efflux 
transport processes, with MRP4 playing a central role 
(Tachikawa et al., 2014). A recent study depicts that micro-
glial beneficial functions combating the toxic effect of Aβ 
in the synapses are inhibited by PGE2 signaling, suggest-
ing the inhibition of this activity as a promising strategy 
to prevent the progression of AD (Johansson et al., 2015). 
Increasing PGE2 clearance by MRP4 may be considered as 
a tool to achieve it, and Nrf2 inducers have been shown to 
up-regulate this ABC transporter.
It is also important to point out that the activity of ABC 
transporters is dependent on ATP production and avail-
ability. It is widely known the essential role of mitochon-
dria in ATP production (among other vital functions in 
the cell), and that mitochondrial dysfunction, very often 
leading to diminished ATP production, is a central hall-
mark in several neurodegenerative diseases. It has been 
demonstrated that Nrf2 induction is able to enhance ATP 
levels by increasing substrates for respiration (Holmstrom 
et al., 2013), and thus induction of Nrf2 could confer both 
the beneficial effect of increasing ATP production and the 
expression of ATP-dependent transporters in the treat-
ment of neurodegenerative diseases.
However, it is also important to note that the increased 
expression of some of these transporters may be linked to 
reduced drug availability in the brain, as they prevent the 
entrance of xenobiotics through the BBB. There are find-
ings pointing at the increase in the expression and activity 
of ABC proteins in the brain in amyotrophic lateral sclero-
sis as the main cause for the lack of effectiveness in vivo of 
those promising drugs in vitro (Jablonski et al., 2015).
SLC transporters
Solute-carrier transporters (SLC) are a family of more than 
300 proteins that mediate the transport of many differ-
ent substrates across membranes. Their activity does not 
depend directly on ATP hydrolysis and they are consid-
ered uptake transporters, as generally are implicated in 
the uptake of molecules into the cell. Nrf2 has been shown 
to positively regulate many of them (Table 1).
Nrf2 up-regulates SLC7A11 and SLC3A2 genes, which 
encode the light and heavy chains subunits of the 
cysteine/glutamate antiporter system xc- (Chorley et  al., 
2012; Hirotsu et  al., 2012). This antiporter mediates the 
uptake of cystine, the anionic form of cysteine, into cells 
in exchange for glutamate, so it plays a critical role in both 
the biosynthesis of intracellular GSH and in the regula-
tion of glutamate release. It was found that the expres-
sion of the two subunits of this antiporter is reduced 
in patients with schizophrenia, which agrees with the 
hypo-glutamatergic neurotransmission hypothesis in the 
pathogenesis of this disease (Lin et al., 2015). However, an 
exacerbated activity of this antiporter may lead to gluta-
mate excitotoxicity and neuronal death in ischemia (Soria 
et al., 2014). Also, higher expression of this subunit was 
found in glioma patients, and was associated with gluta-
mate excitotoxicity, induced seizures and worse prognosis 
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(Robert et al., 2015). Interestingly, there is a positive cor-
relation between overexpression of Nrf2, tumor grade and 
reduced survival in patients with glioma (Zhao et  al., 
2015). It has been proposed that in basal conditions, Nrf1 
negatively regulates cysteine/glutamate antiporter system 
xc-, but in the presence of oxidative stress, Nrf2 is recruited 
to the ARE sequence in the promoter of the gene and acti-
vates its transcription (Tsujita et al., 2014).
SLC1A4 is also positively regulated by Nrf2 and 
encodes ASCT1, a transporter for neutral amino acids, 
being their main substrates L-Ala, L-Ser, L-Cys and L-Thr. 
It is expressed in astrocytes and neurons and represents 
the main uptake of L-Ser in neurons (Kanai et al., 2013). 
Missense mutations in the gene lead to neurological disor-
ders with intellectual disability (Heimer et al., 2015) likely 
due to the alterations in the serine transport.
SLC19A2 gene is up-regulated by Nrf2 and encodes 
the thiamine transporter THTR-1. Thiamine is a cofactor 
of important enzymes in energy metabolism. Mutations 
in this gene leading to decreased activity of the trans-
porter have been associated with hematological diseases 
such as thiamine-responsive megaloblastic anemia. 
Interestingly, thiamine deficiency linked to mutations 
in SLC19A2 was shown to affect mitochondrial complex I 
activity, causing severe complex I deficiency (Scharfe 
et al., 2000). Intracellular deficiency of THTR-1 leads to 
decreased activity of enzymes dependent of thiamine 
diphosphate (TPP) as cofactor, such as the pentose phos-
phate pathway enzyme transketolase, the pyruvate dehy-
drogenase complex, alpha-ketoglutarate dehydrogenase 
and branched chain ketoacid dehydrogenase (Scharfe 
et  al., 2000). There is also increasing evidence that 
suggest alterations in thiamine neurochemistry in AD, 
as thiamine levels and activity of the thiamine-depend-
ent enzymes shown above are decreased in the brain of 
patients (Lu’o’ng and Nguyen, 2011). In this context, Nrf2 
activation would potentially have positive effects by two 
different ways: up-regulating the thiamine transporter 
SLC19A2, and directly up- regulating the expression of 
some thiamine-dependent enzymes as transketolase 
(Xue et al., 2008; Hirotsu et al., 2012).
GSK-3 inhibitors as Nrf2 activators 
in neurodegenerative disorders
GSK-3 is a well-known therapeutic target for AD, as it has 
been shown to hyperphosphorylate tau protein leading 
to its aggregation, and also to mediate Aβ production 
through its precursor APP. GSK-3 inhibitors have beneficial 
effects by reducing the amount of Aβ and the hyperphos-
phorylation of tau in different models of AD (Maqbool 
et  al., 2015). But beyond these effects, GSK-3 inhibitors 
are also able to increase Nrf2 activation, so they can exert 
additional therapeutic effects through this mechanism. 
As it was described earlier in this review, GSK-3 phospho-
rylates Nrf2 in the Neh6 domain, targeting the protein 
for degradation in the proteasome through SCF/β-TrCP 
and therefore inhibiting Nrf2 activity (Rada et  al., 2011). 
Consequently, GSK-3 inhibitors are able to prevent β-TrCP-
dependent degradation of Nrf2, increasing its availability 
and its translocation to the nucleus.
Exacerbated GSK-3β activity has been reported not 
only in AD, but also in other neurodegenerative diseases 
such as PD, and it has been speculated that consequent 
Nrf2 deficiency can be partially responsible for oxidative 
stress and energy-deficits that accompanies these condi-
tions (Rada et al., 2011). Under these pathological condi-
tions GSK-3 inhibitors could also cooperate to increase 
Nrf2 levels.
In this context, it was recently shown that the phy-
toestrogen β-ecdysterone has a protective effect against 
oxidative stress and cell death in the MPTP model of 
PD. The authors show that the phytoestrogen is able to 
increase Nrf2 activity by enhancing Akt signaling path-
ways, and therefore inactivating GSK-3β (Zou et al., 2015). 
Under these conditions, cells showed decreased oxidative 
stress and apoptosis. When Akt was blocked by specific 
inhibitors, the antioxidative properties were lost.
In vivo experiments in SAMP8 mice, a model of AD, 
show that the inhibition of GSK-3β in the brain with 
antisense oligonucleotides leads to an improvement in 
learning and memory. The authors show that GSK-3 sup-
pression was responsible for an increase in the nuclear 
localization of Nrf2 and the levels of its target enzyme 
glutathione S-transferase, which led to decreased oxida-
tive stress. Together with this, tau phosphorylation was 
reduced and there was an improvement in learning and 
memory, suggesting that antisense nucleotide directed at 
GSK-3β may be considered as possible treatment for AD 
(Farr et al., 2014).
A protective role of GSK-3 inhibition-dependent Nrf2 
activation against glutamate excitotoxicity has also been 
shown in the kainate model of epilepsy (Rojo et al., 2008). 
The authors of this study describe that just after an intra-
peritoneal injection with kainate, mice show a rapid 
activation of Akt, followed by GSK inhibition and trans-
location of Nrf2 to the nucleus. However, later on, Akt 
was no longer active, leading to GSK-3 activation and Nrf2 
exclusion from the nucleus, which was associated with 
oxidative-stress and cell death. Treatment of the mice with 
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lithium, a GSK-3 inhibitor, together with sulforaphane, led 
to a decrease in oxidative stress and cell death in kainate-
treated hippocampal slices of wild type, but not in Nrf2 
KO mice. These results suggest that that GSK-3/Nrf2 consti-
tutes a pharmacological target for the prevention of exci-
totoxic neuronal death.
Conclusions
Up to now, most of the Nrf2-mediated therapeutic strate-
gies for neurodegenerative disorders have been focused 
on the prevention of oxidative stress and misfolded 
protein aggregation. There is growing evidence of the role 
of Nrf2 in metabolism and mitochondrial bioenergetics 
and function, which are commonly altered in neurode-
generative disorders. For this reason, pharmacological 
activation of Nrf2 to restore mitochondrial alterations is an 
interesting therapeutic target that needs to be explored for 
the treatment of neurodegenerative disorders. The ability 
of Nrf2 activation to increase the substrates availability 
for the mitochondrial TCA cycle, enhance the mitochon-
drial membrane potential and ATP production is spe-
cially important in neurons, because of their high energy 
demand and their low glycolytic capacity, which can be 
detrimental. As bioenergetics alterations have been found 
in several neurodegenerative conditions such as PD, the 
ability of Nrf2 activators to restore the mitochondrial 
bioenergetics and prevent cell death needs to be further 
explored as a therapeutic target not only for PD but also 
for other neurodegenerative disorders where bioenergetic 
alterations are present.
The Nrf2-dependent regulation of PPARγ and the 
different ABC and SLC transporters also points at the 
potential role of this activation to increase the amyloid 
clearance from the brain, being of special interest for the 
treatment of AD.
It is also worthy to note that the activation of Nrf2 may 
be achieved not only with classical Keap1-targeting com-
pounds, but also through GSK-3 inhibition (and related 
pathways), which increases the range of drug candidates 
for the prevention and treatment of neurodegenerative 
diseases.
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